Aura Biosciences, Inc. AURA R2KR3KPHARMA
Company Overview
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.16.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +4.56% |
| 6 Months: | +35.00% |
| 3 Months: | +14.03% |
| 1 Month: | -2.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.11 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AURA Aura Biosciences, Inc. R2KR3KPHARMA | 7.56 | -4.42 | $781.98M | 0.00% | -74.67% | -95.57% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.04M | 28.61M | 27.91M | 27.24M | 34.87M |
| Operating Income | - | - | -3.63M | -5.93M | -8.80M | -8.89M | -12.81M | -13.82M | -16.05M | -19.44M | -20.28M | -20.49M | -22.31M | -22.76M | - | -29.04M | -28.61M | -27.91M | -27.24M | -34.87M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -28.74M | -28.33M | -27.63M | -26.96M | -34.59M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -27.46M | -26.97M | -26.10M | -25.54M | -33.67M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.00K | 48.00K | 26.00K | 15.00K | 11.00K |
| Net Income | -7.51M | -6.16M | -3.63M | -5.93M | -8.85M | -8.84M | -12.84M | -13.47M | -15.90M | -17.47M | -18.30M | -18.51M | -19.71M | -20.34M | - | -27.48M | -27.02M | -26.13M | -25.56M | -33.69M |
| Diluted EPS | - | - | - | - | -28.53 | -28.33 | -0.44 | -0.46 | -0.54 | -0.46 | -0.48 | -0.48 | -0.40 | -0.41 | -0.42 | -0.55 | -0.47 | -0.40 | - | -0.50 |
| R&D Expense | - | - | 2.85M | 4.18M | 6.63M | 6.37M | 8.28M | 9.51M | 11.29M | 14.40M | 15.12M | 15.43M | 17.05M | 16.88M | 17.04M | 23.34M | 22.88M | 22.18M | - | 27.96M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 60.30M | 84.99M | 96.12M | 112.79M |
| Operating Income | -22.21M | - | -60.30M | -84.99M | -96.12M | -112.79M |
| EBITDA | - | - | -59.12M | -83.70M | -94.89M | -111.66M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -58.76M | -76.27M | -86.81M | -106.08M |
| Tax Provision | - | - | 0 | 137.00K | 112.00K | 108.00K |
| Net Income | -22.21M | - | -58.76M | -76.41M | -86.92M | -106.19M |
| Diluted EPS | - | - | -1.96 | -1.93 | -1.75 | -1.76 |
| R&D Expense | 18.04M | 25.16M | 42.24M | 65.23M | 73.30M | 90.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 22.10M | - | 223.94M | 255.07M | 182.50M | 169.43M |
| Current Assets | - | - | - | 196.70M | 231.79M | 160.62M | 149.74M |
| Cash & Equivalents | - | 17.39M | - | 121.58M | 41.06M | 31.69M | 59.52M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 2.74M | - | 28.35M | 29.23M | 30.53M | 32.52M |
| Current Liabilities | - | 2.66M | - | 10.46M | 12.36M | 14.91M | 18.38M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 20.86M | 19.56M | 18.77M | 17.38M |
| Total Equity | -87.41M | -108.71M | - | 195.58M | 225.85M | 151.97M | 136.91M |
| Shares Outstanding | - | - | - | 37.77M | 49.35M | 50.00M | 63.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -24.32M | - | -54.60M | -63.85M | -79.81M | -84.74M |
| Investing Cash Flow | -771.00K | - | -67.87M | -113.96M | 68.82M | 35.59M |
| Financing Cash Flow | 10.04M | - | 95.63M | 97.29M | 1.59M | 77.16M |
| Capital Expenditure | -771.00K | - | -1.09M | -709.00K | -1.25M | -447.00K |
| Free Cash Flow | -25.09M | - | -55.70M | -64.56M | -81.06M | -85.19M |
| Net Change in Cash | - | - | -26.84M | -80.52M | -9.39M | 28.01M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 20.4% | - | -30.0% | -33.8% | -57.2% | -77.6% |
| ROCE % | -114.2% | - | -28.2% | -35.0% | -57.4% | -74.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | 9.19% | 9.53M | $70.55M |
| 2 | Montanova Capital LLC | 6.95% | 7.21M | $53.33M |
| 3 | Frazier Life Sciences Management, L.P. | 6.85% | 7.10M | $52.54M |
| 4 | Long Focus Capital Management, LLC | 4.94% | 5.12M | $37.88M |
| 5 | Blackrock Inc. | 4.54% | 4.71M | $34.84M |
| 6 | Adage Capital Partners GP L.L.C. | 4.47% | 4.64M | $34.34M |
| 7 | Caligan Partners, LP | 4.14% | 4.30M | $31.81M |
| 8 | Vanguard Capital Management LLC | 3.95% | 4.10M | $30.34M |
| 9 | FCPM III Services B.V. | 3.91% | 4.05M | $30.00M |
| 10 | Orbimed Advisors LLC. | 3.21% | 3.33M | $24.67M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AURA
Is Aura Investments (TASE:AURA) Fully Valued As Mixed Earnings And A New Dividend Stir Interest? - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxPX2FxNnl3SzZvVlFWdXM2b0pmU2d1WDhTMFdOUXNRdElzeXQ1Q09jb1BRTWduWm9WbXpCVzBBVVN1Q2NYSlJuOENxWVVsekdWSHlrSkJjRGV0NHFqS1dleTlCaldhaUsxMVViSDNycUhWVGcwOFBYUVU5VllzUVR6S19aUEFWYXRG?oc=5"…
Aura CEO to speak at Morgan Stanley healthcare event Sept. 16 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOTll2MEJuZl9DYVdHZDQ2ZDFOUHlHZmYtaGpRcVFTOGZqMkQ0RHlTLXlvSGg4dlZhTTF6eU5zRUcxVzgyNkRJdHZYaklDZkV4emRVNm5KZDFJRjNZNGtkS29LVGJyQkRzc0NEMmdHLXVPWEtvN3Q5M1Vjd0c1U0pVUFBuRFQxWWZrRU9TM2…
Aura Minerals(AUGO.US) Director Sells US$10.35 Million in Common Stock - Moomoo
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPTnVBMjdZODJkaXZKbzNiNE9HeVhOb184b0ZnVnhXZjZ1TDhCNVpkbFFDYzRNMEZ6QnFmZG1IRE92cjJwcTZGNDZyQWZERmxjUVdFSWpoajlFRUVyVWZJVFA5eWJMMDI1QWt5LV9KUTlQTnFlOUZCeTFmV0ZTTEZzeUVQS3VRQTd2bjhvan…
Aura Energy Stock Price Forecast. Should You Buy AEE.AX? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiS0FVX3lxTE91SXF3Nm1QbDRUcDZiYzZYbF9zVWJGTEVtcmo1MkJMZjJJYkswYXc0NjA0TmtIVjliVDNXSGM0MHJ5RXBnMWNyUWh4RQ?oc=5" target="_blank">Aura Energy Stock Price Forecast. Should You Buy AEE.AX?</a> …
Aura Investments (TASE:AURA) Could Be Above Fair Value Following Mixed Q2 Earnings - simplywall.st
<a href="https://news.google.com/rss/articles/CBMihAJBVV95cUxPVmlLZmc0UlJsamtFM3pNNFVOYXRUdExZM2VvdWE5djh6b3Y0WGJibTJvSG80Xzh0MjJWTk1DdEdpOGo1dnlOZzZudEtQVWhENlU2bi1DWkJ4OXpxOG1zeVlzaXJWeTMwRDB3YmI3N2NES0ZGbXJKTTE3d3hZTWdfZF9XMko0SlhpSVhwTW…
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxQUWZxR2hKWXpyb3NWTzlxM2dtaXNleGp1RlljdV8wcU94NV9saWc3akpFVWlNYzN3OE1RTzJCX3EweTVreDNpNHRJeGpnN0JoUXhZa2xESktpX3hWUXVBaDRONnhQak9FWFBwOG95eko5TGJFdHlZNG8xLWI3dzZYZHplYUk1Mm5DZzRpel…
AURA — Frequently Asked Questions
What is the current share price of Aura Biosciences, Inc. (AURA)?
As of 2026-09-07 16:24 PDT, Aura Biosciences, Inc. (AURA) trades at $7.56 on NasdaqGM. Its 52-week range is $4.97 to $8.90.
What is the market capitalisation of AURA?
Aura Biosciences, Inc. (AURA) has a market capitalisation of $781.98M on NasdaqGM.
What is the P/E ratio of AURA?
AURA trades at a trailing price-to-earnings (P/E) ratio of -4.42. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.78.
What is the return on equity (ROE) of AURA?
AURA has a return on equity (ROE) of -95.57%. Its return on capital employed (ROCE) is -74.67%.
Is AURA a good stock to buy?
This page provides a data-driven analysis of Aura Biosciences, Inc. (AURA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.